BERKELEY, Calif. (BUSINESS WIRE) Jul 22, 2021
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the pricing of its upsized initial public offering of 19,000,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Caribou. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Caribou, are expected to be $304.0 million. In addition, Caribou has granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
Form S-1/A Caribou Biosciences,
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The Daily Briefing For July 23rd: Futures Higher | Rebel Yell Morning Market Report
wallstreetrebel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreetrebel.com Daily Mail and Mail on Sunday newspapers.
Anaerobic methane oxidation exerts a key control on greenhouse gas emissions
1, yet factors that modulate the activity of microorganisms performing this function remain little explored. In studying groundwater, sediments, and wetland soil where methane production and oxidation occur, we discovered extraordinarily large, diverse DNA sequences that primarily encode hypothetical proteins. Four curated, complete genomes are linear, up to ~1 Mbp in length and share genome organization, including replicore structure, long inverted terminal repeats, and genome-wide unique perfect tandem direct repeats that are intergenic or generate amino acid repeats. We infer that these are a new type of archaeal extrachromosomal element with a distinct evolutionary origin. Gene sequence similarity, phylogeny, and local divergence of sequence composition indicate that many of their genes were assimilated from methane-oxidizing
CRISPR Therapeutics Company Caribou Biosciences Plans $100M IPO
July 6, 2021
A little more than three months after it raised $115 million in a Series C financing round, Caribou Biosciences late last week filed for an initial public offering whose size has not yet been determined, though the company’s S-1 registration statement filed with the U.S. Securities and Exchange Commission, included a placeholder amount of $100 million.
The company plans to trade its shares on the NASDAQ Global Select Market, under the symbol CRBU.
Caribou was established in 2011 by Haurwitz, Doudna, Martin Jínek, a former postdoctoral fellow in Doudna’s lab, now at the University of Zurich, who led the seminal 2012 study leading to the Nobel Prize, and James Berger, professor in the department of biophysics and biophysical chemistry at the Johns Hopkins University School of Medicine.